Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   BioPharma   /   Ook SIRNA

BioPharma« Terug naar discussie overzicht

Ook SIRNA

Volgen
1.786 Posts
Pagina: «« 1 ... 85 86 87 88 89 90 »» | Laatste | Omlaag ↓
  5. ludwig mack 25 mei 2006 21:55
    quote:

    *Elrond* schreef:

    Dat gevoel heb ik dus ook..

    Ik vertrouw deze stijging niet zo, maar aan de andere kant is Sirna wel veel lager gezet en is er ruimte voor wat herstel.

    Een moeilijke beslissing..

    Groet,

    Elrond
    die daling was al ingezet voor emissiebekendmaking: je voorzichtigheid is dus terecht :)
  6. gustaaf1e 25 mei 2006 22:24
    quote:

    -Anna- schreef:

    Pas op. 9 miljoen aandelen erbij op 4.66. Koers wordt omhoog gezet om ze er uit te gooien en winst te nemen. potentieel is een stuk minder de komende tijd denk ik.
    Anna, principieel doet het er niet zo toe, maar ik lees hierboven 9 miljoen stuks a $5,- toch? Of zie ik dat niet goed?
    Guus
  8. gustaaf1e 25 mei 2006 23:12
    Ik weet niet of die 9 miljoen+ aandelen al op korte termijn verkocht mogen worden. Maar als ze alle aandelen in de markt kwijt willen, moet er nog een aantal dagen zo'n omzet als vandaag gemaakt worden. De bank heeft natuurlijk ook baat bij hogere koersen en zal gespreid verkopen.

    Guus
  9. [verwijderd] 26 mei 2006 10:36
    BIOSTEPHAN BERICHT OP ANDER DRAADJE:
    ------------------------------------
    RNAi beleggers oppassen! de bladen staan vol met waarschuwingen en beschreven bijeffecten.

    RNAi Safety Comes Under Scrutiny
    Jennifer Couzin

    What began as an effort to craft a better hepatitis therapy using a strategy called RNA interference has ended in the deaths of dozens upon dozens of mice--a harsh safety alarm for biomedical researchers looking to RNAi as a treatment for HIV, cancer, neurodegenerative diseases, and more.

    The results, from gene therapist Mark Kay of Stanford University in California, come 3 years after he reported that a treatment based on the gene-silencing technique inhibited replication of the hepatitis B virus in mouse livers. This time around, Kay's team administered a refined version of the RNAi treatment to more than 50 infected mice.

    "We saw for the first couple days exactly what we expected," says Kay's postdoctoral fellow Dirk Grimm, who helped lead the studies. But within a week or two, the mice began falling sick, their skin turning yellow from liver damage. More than 150 animals died, and many others suffered liver toxicity. Lowering the amount of virus given eliminated the harsh effects but also erased the treatment's success.

    "There's something that we don't understand going on here," says Timothy Nilsen, who heads the Center for RNA Molecular Biology at Case Western Reserve University in Cleveland, Ohio. Although Kay and Grimm were taken aback by the devastating toxicity, they and others retain confidence in RNAi. "I really think it can still work," says Kay.

    RNAi has become enormously popular in the last few years. It involves blocking the activity of genes, including those linked to disease, with short sequences of RNA complementary to a gene's sequence. Companies are already testing in people RNAi treatments for a respiratory virus and for macular degeneration.

    Figure 1 Interference problem. Compared to the liver of a healthy mouse (above), an RNAi treatment destroys the liver of a treated animal (below).

    CREDIT: M. KAY/STANFORD UNIVERSITY

    Those trials, for which no significant safety problems have been disclosed so far, rely on simply introducing RNA molecules into the body. In contrast, Kay's team packages genes encoding small RNA molecules into viruses stripped of other genetic material, a strategy much like traditional gene therapy. Once injected, the viruses infect cells and keep producing the small RNAs, allowing a single dose to go a long way.

    For its RNAi tests, Kay's team uses an adeno-associated virus (AAV), which homes to the liver. Indeed, 90% of the virally delivered RNA genes ended up there, says Grimm. Yet the virus is probably blameless; injections of an empty virus didn't cause problems in the mice. To explore whether specific RNA sequences might be the culprits, the Stanford team created dozens of viruses making other RNA sequences and injected them into mice without hepatitis B, some genetically altered and some normal. Out of all 49 sequences tested, 23 were lethal in every case, killing the animals within 2 months. Another 13 were "severely toxic" to the liver, they write in Nature. As with many treatments, dosing seems to correlate with risk: Kay's team safely thwarted hepatitis B in mice by injecting an AAV that makes fewer RNA sequences.

    The results are "not surprising in retrospect," says John Rossi of City of Hope in Duarte, California, who's working on an RNAi therapy for HIV. Too many extra RNA molecules may disrupt a cell's own internal RNAi machinery, he explains. Kay's group suggests that the extra small RNAs compete for a protein that transports a cell's own RNAs.

    A company called Sirna Therapeutics in San Francisco, California, still plans to test a nonviral RNAi strategy on people with hepatitis C next year. The firm "has spent a hell of a lot of time and effort putting [small RNAs] into animals and nonhuman primates … looking for toxicity, and we haven't seen anything like this," says Barry Polisky, Sirna's chief scientific officer. Like Kay and others, Polisky worries that these new findings will be seen as an indictment of RNAi therapy, even though he is confident that injecting small RNAs alone is less hazardous than the viral approach. Not everyone's convinced. "I think it's premature to say anything is safer at this point," says Nilsen.

  10. [verwijderd] 26 mei 2006 10:38
    Twee stukjes:

    -------------

    Sirna has granted a 30-day option to the underwriters to purchase up to 1,350,000 additional shares of common stock at the public offering price to cover over-allotments, if any.

    -------------

    PRICE STABILIZATION, SHORT POSITIONS
    In connection with this offering, the underwriters may engage in activities that stabilize, maintain or otherwise affect the price of our common stock, including:

    - stabilizing transactions;
    - short sales;
    - purchases to cover positions created by short sales;
    - imposition of penalty bids; and
    - syndicate covering transactions.

    Stabilizing transactions consist of bids or purchases made for the purpose of preventing or retarding a decline in the market price of our common stock while this offering is in progress. These transactions may also include making short sales of our common stock, which involves the sale by the underwriters of a greater number of shares than they are required to purchase in this offering and purchasing shares of common stock on the open market to cover positions created by short sales. Short sales may be

    “covered” shorts, which are short positions in an amount not greater than the underwriters’ over-allotment option referred to above, or may be “naked” shorts, which are short positions in excess of that amount.
    The underwriters may close out any covered short position by either exercising their over-allotment option, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the over-allotment option.
    Naked short sales are sales in excess of the over-allotment option. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned there may be downward pressure on the price of shares in the open market after pricing that could adversely affect investors who purchase in this offering.
    The underwriters also may impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of that underwriter in stabilizing or short covering transactions.
    In addition, in connection with this offering, certain of the underwriters (and selling group members) may engage in passive market making transactions in our common stock on the Nasdaq National Market prior to the pricing and completion of the offering. Passive market making consists of displaying bids on the Nasdaq National Market no higher than the bid prices of independent market makers and making purchases at prices no higher than these independent bids and effected in response to order flow. Net purchases by a passive market maker on each day are limited to a specified percentage of the passive market maker’s average daily trading volume in the common stock during a specified period and must be discontinued when such limit is reached.
    As a result of these activities, the price of our common stock may be higher than the price that otherwise might exist in the open market. If these activities are commenced, they may be discontinued by the underwriters at any time. If the underwriters may carry out these transactions on the Nasdaq National Market, in the over-the-counter market or otherwise.
  19. [verwijderd] 23 juni 2006 14:37
    European Patent Office Significantly Limits Scope of Kreutzer-Limmer RNAi Patent Claim
    Long-awaited ruling on Kreutzer-Limmer patent validates objections filed by
    Sirna Therapeutics, sanofi-aventis, Atugen, and others
    SAN FRANCISCO, June 23 /PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc. (Nasdaq: RNAI), a leading RNAi-based therapeutics company, announced today that its objections to the Kreutzer-Limmer patent in Europe were accepted by the European Patent Office, resulting in both a significant narrowing of the patent claims and substantial limitations on the commercial utility of that patent.

    "We contended from the very beginning that the Kreutzer-Limmer patent would not stand up to scientific and legal scrutiny and that its true commercial and scientific value in the field of RNA medicines has been miscast and misunderstood," stated Howard W. Robin, President and Chief Executive Officer of Sirna Therapeutics. "We will continue to oppose unsubstantiated patent claims while growing our own intellectual property estate to seek to ensure that we have the freedom to advance both our own and our partners' RNAi-based therapies through the clinic and into the market."

    European patent No: EP1144623B1 (the Kreutzer-Limmer patent), which was opposed by Sirna, AstraZeneca PLC, Atugen (SR Pharma PLC), Janssen Pharmaceutica N.V., and sanofi-aventis, was significantly narrowed and now only covers methods of making and using double stranded RNA with lengths and structures of limited usefulness as RNAi-based therapeutics.

    "The claims of the Kreutzer-Limmer patent as granted are now limited to chemical structures, that in our experience, are obsolete and essentially ineffective as viable RNAi-based therapeutics," stated Bharat Chowrira, Ph.D., J.D. Chief Patent Counsel of Sirna Therapeutics. "We believe, therefore, that this patent has no impact on our current or future programs, and perhaps more importantly, that it does not provide any meaningful intellectual property protection in the field of RNAi-based therapeutics."

    Sirna believes that its issued and pending patents in siRNA design, chemistry, synthesis, delivery and manufacturing together with its target patents and microRNA patents, give the company a dominant intellectual property portfolio in the field of RNAi-based therapeutics.


  20. [verwijderd] 23 juni 2006 14:40
    ter vergelijking even het bericht van gisteren van alny. Leuk om te zien hoe elk PB van een bedrijf met een emmer zout moet worden genomen.

    Alnylam Reports Positive Outcome in European Opposition Proceedings on Kreutzer-Limmer I Patent
    Thursday June 22, 2:49 pm ET
    Amended Claims Broadly Cover siRNAs with Key Features Critical for RNAi Therapeutics

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 22, 2006--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has upheld key features of the company's Kreutzer-Limmer I patent (EP 1144623) with claims covering small interfering RNAs (siRNAs), the molecules that mediate RNAi. This patent was originally granted in Europe on August 28, 2002, but was opposed by several parties, a legal practice that is common for European patents. The amended patent claims cover certain structural requirements for siRNAs that are important for therapeutic activity.
    ADVERTISEMENT



    "The outcome of the European opposition proceedings today is a positive step forward in Alnylam's strategic consolidation of intellectual property needed for advancement of RNAi therapeutics as products. Today's ruling adds strength to an intellectual property estate for RNAi therapeutics that contains well over 150 patents issued in major markets," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam Pharmaceuticals. "In addition to this ruling, Alnylam's intellectual property position was greatly strengthened with the recent issuance by the United States Patent and Trademark Office of our exclusively held Tuschl II patent. Further, we expect issuance of new patents from the Tuschl II series within the next 6 months. Alnylam's intellectual property estate enables our efforts to build value through major partnerships, target-by-target therapeutic licenses in our InterfeRx program, and licenses to the reagent and services market, where we have an unmatched track record of execution."

    The Kreutzer-Limmer I patent that is the subject of the EPO's ruling (EP 1144623) is one of many components of Alnylam's intellectual property (IP) estate, which in aggregate, broadly covers the "fundamental," chemistry, and target IP necessary for the development and commercialization of RNAi therapeutics. As originally granted, the claims of this patent covered siRNAs with up to 25 nucleotides complementary to a target gene, and were obtained by use during prosecution of a so-called "Disclaimer Practice" that was deemed to be not applicable as a result of a separate ruling issued by the Enlarged Board of the EPO. In consequence, the claims were amended to cover siRNAs with a shorter length and other required features. Specifically, the claims in the upheld patent cover methods, medicaments, and uses of siRNAs with:

    a region of complementarity to a target gene between 15 and 21 nucleotides in length;
    an overall length of between 15 and 21 base pairs; and,
    a double-stranded structure that is stabilized by a chemical linkage of the single strands, such as and including standard modifications used for stabilization.
    "We're gratified that the EPO has recognized the inventive contributions of Drs. Kreutzer and Limmer to the field of RNAi therapeutics," said Robert Millman, Chief Intellectual Property Counsel of Alnylam Pharmaceuticals. "The amended claims granted through the oral opposition proceedings cover features of siRNAs that are critical for RNAi therapeutics. Importantly, the patent covers methods, medicaments, and uses of siRNAs in Europe, the world's second largest pharmaceutical market."

    Alnylam's IP estate includes issued or granted fundamental patents and patent applications that claim the broad structural and functional properties of synthetic RNAi therapeutic products. These include: the recently issued Tuschl II patent, U.S. Patent No. 7,056,704, which broadly covers methods of making siRNAs to silence any and all disease targets; a separate Tuschl II series patent application, U.S. 10/832,248, for which claims were recently allowed that broadly cover methods of making siRNAs with or without chemical modifications; and other pending applications from the Tuschl II series. In addition to the Kreutzer-Limmer I patent that was the subject of today's ruling (EP 1144623), Alnylam's IP estate includes other Kreutzer-Limmer I and II patents acquired through the July 2003 merger with Ribopharma AG (now Alnylam Europe AG): EP 1214945, covering compositions, methods, and uses of siRNAs with a length between 15 and 49 nucleotides; and EP 1352061, covering therapeutic compositions, methods, and uses of siRNA and derivatives directed toward over 125 disease targets. Additional fundamental patents and patent applications licensed to Alnylam on an exclusive or non-exclusive basis include those of Crooke (U.S. Patent Nos. 5,898,031 and 6,107,094), Fire and Mello (U.S. Patent No. 6,506,559), Glover et al. (EP 1230375), and Tuschl et al. (Tuschl I, patent pending), among others. In addition, Alnylam has a broad worldwide license for RNAi therapeutics from Isis Pharmaceuticals, Inc. for more than 150 issued patents pertaining to the chemical modification of oligonucleotides used to introduce "drug-like" properties in siRNAs. These include key issued patents for chemical stabilization of siRNAs such as phosphorothioate and 2'-O-methyl modifications (Buhr, U.S. Patent No. 6,473,205) and 2'-fluoro modifications (Cook, U.S. Patent Nos. 5,670,633; 6,005,087; and 6,531,584) of oligonucleotides.

1.786 Posts
Pagina: «« 1 ... 85 86 87 88 89 90 »» | Laatste |Omhoog ↑

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
ASR Nederland 50,760 +2,01 +4,12%
THEON INTERNAT 17,940 +0,70 +4,06%
Alfen N.V. 12,645 +0,30 +2,39%
Flow Traders 25,700 +0,52 +2,07%
NN Group 46,170 +0,69 +1,52%
Aegon 6,498 +0,09 +1,47%
ABN AMRO BANK N.V. 17,635 +0,18 +1,03%
RANDSTAD NV 38,530 +0,38 +1,00%
SHELL PLC 32,745 +0,28 +0,85%
B&S Group SA 4,305 +0,04 +0,82%
INPOST 17,420 +0,13 +0,75%
VASTNED 28,400 +0,20 +0,71%
ForFarmers 3,580 +0,03 +0,70%
KPN 3,501 +0,02 +0,66%
CTP 16,400 +0,10 +0,61%
Accsys 0,503 +0,00 +0,60%
BESI 117,550 +0,70 +0,60%
JDE PEET'S 16,910 +0,10 +0,59%
TomTom 4,254 +0,02 +0,57%
UNILEVER PLC 52,660 +0,28 +0,53%
ADYEN NV 1.855,800 +9,80 +0,53%
ING 16,794 +0,08 +0,49%
AZERION 1,648 +0,01 +0,49%
ACOMO 18,340 +0,08 +0,44%
Wolters Kluwer 178,200 +0,70 +0,39%
ALLFUNDS GROUP 4,950 +0,01 +0,28%
SBM Offshore 18,260 +0,04 +0,22%
PostNL 1,055 +0,00 +0,19%
Sligro 10,760 +0,02 +0,19%
Van Lanschot Kempen NV 49,100 +0,05 +0,10%
Fagron 20,000 +0,02 +0,10%
PROSUS 45,030 +0,01 +0,02%
Avantium 1,892 0,00 0,00%
RELX 48,600 0,00 0,00%
RENEWI 10,260 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
Philips Koninklijke 24,150 -2,93 -10,82%
Vopak 42,380 -2,96 -6,53%
EBUSCO HOLDING 0,634 -0,02 -2,45%
AMG Critical Materials N.V. 15,970 -0,29 -1,78%
JUST EAT TAKEAWAY 12,710 -0,23 -1,78%
DSM FIRMENICH AG 103,550 -1,70 -1,62%
HEIJMANS KON 34,150 -0,55 -1,59%
Sif Holding 11,200 -0,18 -1,58%
IMCD 147,750 -2,35 -1,57%
UMG 28,450 -0,37 -1,28%
Eurocommercial Properties 23,800 -0,30 -1,24%
Air France-KLM 8,580 -0,10 -1,17%
BAM 4,856 -0,06 -1,14%
Arcadis 50,800 -0,55 -1,07%
EXOR NV 94,800 -0,90 -0,94%
SIGNIFY NV 21,280 -0,20 -0,93%
Pharming 0,880 -0,01 -0,90%
Corbion 22,940 -0,20 -0,86%
WDP 21,060 -0,18 -0,85%
Akzo Nobel 59,260 -0,50 -0,84%
Ahold Delhaize 33,740 -0,28 -0,82%
Basic-Fit 22,460 -0,18 -0,80%
Wereldhave 15,060 -0,12 -0,79%
Aperam 30,140 -0,24 -0,79%
OCI 10,920 -0,08 -0,73%
NSI 22,150 -0,15 -0,67%
Fugro 14,820 -0,10 -0,67%
AALBERTS NV 36,880 -0,24 -0,65%
Brunel 9,460 -0,06 -0,63%
Galapagos 25,600 -0,16 -0,62%
CM.COM 6,440 -0,04 -0,62%
NX FILTRATION 3,230 -0,02 -0,62%
AMX 863,82 -4,97 -0,57%
Kendrion 10,440 -0,06 -0,57%
FASTNED 19,900 -0,10 -0,50%
ASCX 1.336,83 -5,29 -0,39%
TKH 37,400 -0,14 -0,37%
Nedap N.V. 59,800 -0,20 -0,33%
Heineken 78,460 -0,24 -0,30%
ArcelorMittal 27,640 -0,07 -0,25%
ASMI 569,600 -1,00 -0,18%
ASML 715,700 -0,50 -0,07%
AEX 946,78 -0,28 -0,03%
vlag naam koers verschil relatief verschil
AEX 946,78 -0,28 -0,03%
AEX GR 3.720,83 -0,65 -0,02%
DE40 22.844,50 0,00 0,00%
FTSE 100 8.748,52 -18,21 -0,21%
Europe50^ 5.533,84 0,00 0,00%
US30^ 44.592,10 +46,00 +0,10%
Nasd100^ 22.187,00 +21,60 +0,10%
US500^ 6.133,16 +5,31 +0,09%
Japan225^ 39.132,40 -186,50 -0,47%
VD-NEW 17,76 -0,36 -1,97%
#/^ Index indications calculated real time, zie disclaimer